Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 25, 2016 19:00 ET | Source: MediciNova, Inc.

Options on MediciNova Common Stock Listed on CBOE

LA JOLLA, Calif., Sept. 25, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
July 24, 2016 19:00 ET | Source: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis

LA JOLLA, Calif., July 24, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
July 13, 2016 06:30 ET | Source: MediciNova, Inc.

MediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS

LA JOLLA, Calif., July 13, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
June 29, 2016 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana

LA JOLLA, Calif., June 29, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
June 26, 2016 19:00 ET | Source: MediciNova, Inc.

MediciNova Added to Russell 3000® Index and Russell Global Index

LA JOLLA, Calif., June 26, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
May 25, 2016 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana

LA JOLLA, Calif., May 25, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
April 20, 2016 06:00 ET | Source: MediciNova, Inc.

MediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada

LA JOLLA, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
March 30, 2016 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces Publication of Positive Findings from Completed Phase 1b Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence

LA JOLLA, Calif., March 30, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
March 27, 2016 19:00 ET | Source: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 in China

LA JOLLA, Calif., March 27, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...
March 23, 2016 19:00 ET | Source: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia

LA JOLLA, Calif., March 23, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock...